BIOTRAK™ REAL-TIME VIABLE PARTICLE COUNTER - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BIOTRAK™ REAL-TIME VIABLE PARTICLE COUNTER

A real-time viable particle counter such as the TSI BioTrak™ detector can continuously monitor an aseptic process for airborne viable particles, and per the current GMP guidance, monitor total particle counts simultaneously using an existing single particle monitoring probe. Data is logged and alarms generated in real-time using a Facility Monitoring System. No need to intervene and cleanup following a plate change or load growth media into the isolator, no need to add additional interfaces. If there is a microbiological excursion, everyone will know right away..

In a single portable instrument the TSI BioTrak™ Real-time viable particle detector counts airborne particles compliant to ISO 21501-4and has a 28.3 lpm sample flow rate. It then analyzes each particle for viability, finally it collects all optically analyzed particles on a collection filter to enable laboratory based speciation analysis. BioTrak™ – the real-time viable particle counter that delivers airborne viable particle count data you can trust, moving you towards real-time quality assurance and process control.

Contact TSI (www.tsi.com) today to arrange an evaluation and find out more about the many immediate use applications the BioTrak detector has to offer. Gain a competitive advantage today, the potential benefits this technology has to offer are too great to ignore.

Further information on Biotrak visit: www.tsi.com/biotrak-9510 or E-Mail: emea.tsi@tsi.com

About TSI Incorporated

TSI Incorporated serves a global market by investigating, identifying and solving measurement problems. As an industry leader in the design and production of precision instruments, TSI partners with research institutions and customers around the world to set the standard for measurements relating to aerosol science, air flow, health and safety, indoor air quality, fluid dynamics and biohazard detection.

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
FindPharma Custom Search

Click here